UK MHRA MDSAP Membership: Streamlining Audits for UK, US, Canada, and More

UK MHRA MDSAP Membership: Streamlining Audits for UK, US, Canada, and More

The UK's MHRA announced on June 22, 2026, its intention to become a full member of the Medical Device Single Audit Program (MDSAP). This episode explores the significant impact of this decision on medical device manufacturers. We discuss how full membership will streamline the audit process, allowing a single quality management system audit to satisfy requirements for the UK, US, Canada, Australia, Brazil, and Japan. We also cover the strategic implications for the UK's post-Brexit regulatory framework and provide practical steps for regulatory and quality teams to prepare for this change. Key Questions: - What is the Medical Device Single Audit Program (MDSAP)? - What did the UK MHRA announce on June 22, 2026, regarding its MDSAP status? - How does full MDSAP membership differ from the UK's current affiliate status? - Which countries' regulatory requirements can be met with a single MDSAP audit? - How will this change reduce the audit burden for medical device manufacturers? - What does this move signal about the UK's post-Brexit regulatory strategy? - What practical steps should regulatory teams take to prepare for this transition? - Could this development make the UK a more attractive market for device companies? Sources: - https://medtech.pharmaintelligence.informa.com/MT148334/MDSAP-Move-Underlines-MHRAs-Global-Device-Regulatory-Ambitions How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets. Whether you're dealing with changes like the UK's integration into MDSAP or planning a multi-market launch, our team of local experts and advanced AI tools can create an efficient regulatory strategy. We act as your local representative and manage technical dossier submissions to get your products approved faster. To learn how we can streamline your market access, visit us at https://pureglobal.com, email info@pureglobal.com, or explore our free AI regulatory tools and global device database at https://pureglobal.ai.

Singapore HSA COVID-19 IVD Reclassification: Class C Requirements from 2026

Singapore's Health Sciences Authority (HSA) is reclassifying all COVID-19 in-vitro diagnostic (IVD) tests from the highest-risk Class D to Class C, effective June 2, 2026. This episode details the reasons for this regulatory shift as COVID-19 becomes endemic, explains the differences between Class C and Class D requirements, and outlines the practical impact on technical documentation, quality management systems, and post-market surveillance for IVD manufacturers marketing products in Singapore. Key Questions: - What is the new risk classification for COVID-19 IVD tests in Singapore? - Why did Singapore's Health Sciences Authority (HSA) make this change? - When does this new classification officially take effect? - How does the Class C regulatory pathway differ from the Class D pathway for IVDs? - What are the specific changes to technical documentation and submission requirements? - Will existing COVID-19 IVDs need to be re-registered under the new class? - How does this reclassification impact post-market surveillance obligations? - What immediate actions should regulatory teams take to prepare for this transition? Sources: - https://www.morulaa.com/singapore-hsa-announces-regulatory-updates-for-medical-devices-ivds/ - https://www.hsa.gov.sg/medical-devices/guidance-documents How Pure Global can help: Navigating regulatory changes like Singapore's IVD reclassification requires local expertise and a clear strategy. Pure Global provides comprehensive support for MedTech and IVD companies, acting as your local Singapore Registrant and managing the entire registration process. Our team of experts and advanced AI tools can help you efficiently update your technical dossiers, adapt your quality management system, and ensure a seamless transition to the new Class C requirements. To learn how we can accelerate your market access in over 30 countries, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.

India CDSCO Proposes New Medical Device Import Rules for Hospitals (2026)

India's drug regulator, the CDSCO, has proposed a new framework to allow hospitals to directly import a list of 80 high-end medical devices, such as MRI and CT scanners. This episode explores the potential policy shift, which aims to bypass the traditional licensed importer route to speed up access to advanced technology. We cover the implications for international manufacturers, the patient safety and post-market surveillance concerns raised by domestic industry, and the practical steps regulatory and quality teams should take now to prepare for this change. Key Questions: - What is India's CDSCO proposing for high-end medical device imports as of June 2026? - Which types of devices like MRI and CT scanners are on the proposed direct import list? - How could this policy change the market access strategy for international manufacturers in India? - What are the primary patient safety concerns with allowing hospitals to import devices directly? - Why is post-market surveillance a critical challenge in this proposed framework? - How does this proposal differ from the existing Medical Device Rules, 2017? - What are the potential benefits that are driving this proposed policy change? - What practical actions should regulatory and quality teams take during the stakeholder consultation phase? Sources: - https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/plan-in-the-works-to-let-hospitals-import-med-equipment-directly/articleshow/111107931.cms - https://whalesbook.com/news/india-proposes-direct-import-path-for-high-end-medical-gear - https://www.livemint.com/industry/govt-plans-to-allow-hospitals-to-directly-import-high-end-medical-equipment-11718854992523.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like those emerging in India. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure compliance. By combining in-country expertise with advanced AI technology, we streamline the registration process and help you monitor critical regulatory changes. To learn how we can help you access over 30 global markets faster, visit us at https://pureglobal.com, email info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

Health Canada's 2026 Hyperbaric Chamber Warning: Compliance for Unlicensed Devices

Health Canada issued a public advisory on June 16, 2026, warning that unauthorized soft-shelled hyperbaric chambers are illegal to sell, import, or advertise in Canada. This episode breaks down the specific health risks identified, the regulatory status of these devices, and the enforcement actions being taken. We provide practical compliance steps for manufacturers and distributors of wellness devices to ensure their products meet Canadian regulations and avoid similar enforcement actions. Key Questions: - What specific risks did Health Canada identify with soft-shelled hyperbaric chambers? - Why are these devices classified as illegal Class II medical devices in Canada? - What enforcement actions can manufacturers and distributors expect from Health Canada? - How does this advisory impact the broader 'wellness' device industry? - What are the unproven therapeutic claims associated with these unlicensed devices? - How can companies audit their product portfolios for compliance with Health Canada's regulations? - What steps should importers take to verify the licensing status of products from their partners? - How can you ensure your marketing claims do not trigger regulatory scrutiny? Sources: - https://www.canada.ca/en/health-canada/news/2026/06/public-advisory---unauthorized-soft-shelled-hyperbaric-chambers-may-pose-serious-health-risks.html - https://www.cp24.com/news/this-medical-device-may-cause-serious-health-risks-and-even-death-health-canada-warns-1.7000000 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 countries, including Canada. We use advanced AI to streamline compliance and ensure your products, from initial classification to post-market surveillance, meet all requirements. Whether you're a startup or a multinational, we can help you navigate complex regulatory landscapes like Health Canada's requirements and avoid costly compliance issues. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Health Canada MDEL Regulations 2026: What Importers and Foreign Manufacturers Need to Know

Health Canada has finalized amended regulations for its Medical Device Establishment Licence (MDEL) framework, which come into force on December 14, 2026. This episode breaks down the critical changes, including the removal of the MDEL requirement for foreign distributors who sell through a licensed Canadian importer and the new obligation for Canadian MDEL holders to provide a complete list of their suppliers. We explore the practical impact on foreign manufacturers, Canadian importers, and distributors, and outline key steps to ensure compliance before the deadline. Key Questions: - What are the key changes in Health Canada's updated MDEL framework? - When do the new MDEL regulations come into force? - Do foreign distributors still need an MDEL to sell medical devices in Canada? - What new information must Canadian MDEL holders provide to Health Canada? - How does this change affect the responsibilities of Canadian importers? - What is the impact on foreign manufacturers selling into the Canadian market? - What practical steps should my company take to prepare for the December 14, 2026 deadline? - How will the new supplier list requirement enhance supply chain traceability? - Does my company need to update its distribution agreements for the Canadian market? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/bulletins/modernize-medical-device-establishment-licensing-phase-2.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/other-regulatory-requirements.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/contact-us.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex market access requirements. For companies impacted by Health Canada's new MDEL rules, we offer expert regulatory strategy, act as a local representative, and help update quality systems to ensure seamless compliance. Our technology-driven approach streamlines technical dossier management and submission, helping you access over 30 global markets faster. Learn more about our free AI tools and global device database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com to discuss your market access goals.